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Background: There are only limited data on whether HIV infection occurs within the liver; therefore, we explored
early and late stages of the HIV life cycle in two hepatocyte cell lines – Huh7.5 and Huh7.5JFH1 – as well as in
primary human hepatocytes.
Results: Integrated HIV DNA was detected in Huh7.5 and Huh7.5JFH1 cells, as well as in primary hepatocytes, and
was inhibited by the integrase inhibitor raltegravir in a dose-dependent manner. HIV p24 protein was also detected
in cell culture supernatants at days 1, 3, 5, and 7 post-infection and was inhibited by AZT, although levels were
modest compared to those in a lymphocyte cell line. Culture supernatants from HIV-infected hepatocytes were
capable of infecting a non-hepatic HIV indicator cell line.
Conclusions: These results indicating low-level HIV replication in hepatoctyes in vitro complement evidence
suggesting that HIV has deleterious effects on the liver in vivo.
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HIV infection is associated with a number of hepatic
and biliary tract disorders, hepatomegaly, and hepatic
steatosis [1-5]. Moreover, liver enzyme elevations are fre-
quent in persons with HIV infection even in the absence
of viral hepatitis [6,7]. Additionally, we have recently
reported that HIV RNA levels are positively associated
with FIB-4 score – a non-invasive serum index of hep-
atic fibrosis – in HIV mono-infected persons even after
controlling for other causes of liver disease, thus sup-
porting a potential association between HIV infection
and hepatic fibrosis in vivo [8]. In vivo data further dem-
onstrate the presence of HIV RNA, proviral DNA, and
viral proteins in several hepatic cell types, including
hepatocytes (reviewed in [9]). Thus, the effects of HIV
itself on the liver deserve careful consideration.
Hepatitis C virus (HCV) – a major cause of chronic
liver disease – is a significant public health threat world-
wide with ~130 million infected persons [10]. Due to
their shared routes of transmission, HIV/HCV co-
infection is frequent, and liver disease is a major cause* Correspondence: jason.blackard@uc.edu
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reproduction in any medium, provided the orof morbidity and mortality in several HIV-positive
cohorts [11-13]. It is well established that HIV co-
infection is associated with accelerated liver disease and
decreased HCV treatment response rates (reviewed in
[14]). Until recently, in vitro systems to study the
complete HCV life cycle were unavailable. Fortunately, a
novel cell culture system – hereafter referred to as
Huh7.5JFH1 – capable of producing infectious HCV par-
ticles now permits examination of the complete life cycle
in the presence or absence of other pro-viral or antiviral
factors [15-18]. Therefore, given the possibility that HIV
infection of hepatocytes could have a profound effect on
the liver, we investigated early and late stages of the HIV
life cycle in the Huh7.5 and Huh7.5JFH1 hepatocyte cell
lines, as well as in primary human hepatocytes. Such
investigations represent an important first step in im-
proving our understanding of HIV pathogenesis in the
liver and characterizing pathways by which HIV inter-
acts with co-morbid conditions such as viral hepatitis
and/or alcoholic liver disease.
Methods
Cell lines and reagents
The Huh7.5 cell line – generated by curing an HCV
replicon-containing cell line with interferon [19] – was
provided by Apath LLC (St. Louis, MO). The Huh7.5JFH1td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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virions – was provided by Dr. Guangxiang Luo [20]. The
following reagents were obtained through the AIDS Re-
search and Reference Reagent Program, Division of
AIDS, NIAID, NIH: zidovudine (AZT), TZM-bl cells
[21] from Drs. John Kappes and Xiaoyun Wu and Tran-
zyme Inc., plasmids pNL4-3 [22] from Dr. Malcolm
Martin and pYK-JRCSF [23] from Drs. Irvin Chen and
Yoshio Koyanagi, and raltegravir (catalog #11680) from
Merck & Company, Inc. Jurkat and 293 T cells were
obtained from ATCC. Primary human hepatocytes were
purchased from Diagnostic Hybrids (Athens, OH) or BD
Biosciences (San Jose, CA) after isolation from non-
transplantable livers perfused with HEPES buffer followed
by collagenase treatment. Hepatocytes were dissociated
mechanically and filtered to obtain a cell suspension.
After non-adherent cells were removed, trypan blue ex-
clusion demonstrated >90% viability.
Virus preparation
HIVNL4-3 (CXCR4-utilizing) and HIVYK-JRCSF (CCR5-
utilizing) were prepared by transfection of 1 × 106 293 T
cells per well in a 24-well plate with 1 μg of the appro-
priate full-length infectious HIV plasmid using the
FuGene6 transfection reagent (Roche). Transfected cells
were incubated at 37°C for an additional 48–72 hours.
Virus-containing supernatants were passed through a
0.20 μm filter to remove cellular debris and precipitated
in polyethylene glycol at 4°C. Precipitated virus was then
centrifuged at 14,000 g for 20 minutes, resuspended in
PBS, and frozen at −80°C until use. The level of p24
protein in cell culture supernatants was determined by
p24 ELISA (Perkin-Elmer, Boston,MA; lower limit of
detection = 4.3 pg/mL) or by titering on TZM-bl cells.
For experiments quantifying integrated HIV DNA,
viruses were pre-treated with DNase I at 20 U/mL in
10 mM MgCl2 for 1 hour at room temperature to elim-
inate any cellular DNA carryover from virus production.
HIV infections
5 × 105 cells (Huh7.5, Huh7.5JFH1, or primary hepato-
cytes) were seeded per well of a 24-well, collagen-coated
plate and incubated at 37°C in 5% CO2 with infectious
HIV at a multiplicity of infection (MOI) of 0.25-1.0 in a
volume of ~500 uL per well unless otherwise noted.
After 4 hours, viruses were removed by washing cells
five times with buffer, and fresh medium was added.
Cells and cell culture supernatants were removed at vari-
ous timepoints post-infection to measure HIV p24 pro-
tein levels by ELISA. For Western Blots, 100,000 cells
were harvested at days 1, 3, 5, and 7 post-infection and
lysed in 100 uL of buffer; 10 uL was loaded per well.
HIV p24 was detected using a 1:1000 dilution of a rabbit
monoclonal antibody (Ab) from Epitomics (Burlingame,CA; catalog # 1523–1) as the primary Ab and a 1:5000
dilution of a rabbit polyclonal Ab to mouse IgG from
Abcam (Cambridge, MA; catalog # 6728) as the second-
ary Ab. As an additional loading control, glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was detected
using a rabbit polyclonal Ab from Santa Cruz Biotech-
nology (Santa Cruz, CA; catalog #SC-25778) at a 1:1000
dilution.
For preparation of non-infectious HIV with function-
ally intact envelope glycoproteins, HIVNL4-3 was first
prepared by transfection of 293 T cells as described
above. After filter sterilization, virus was inactivated by
adding 250 uM of aldrithiol-2 (AT-2; Sigma-Aldrich) to
the filtered supernatants as described elsewhere [24].
AT-2-treated viruses were then incubated with the TZM
indicator cell line to confirm that they were not infec-
tious (data not shown), and HIV-1 p24 ELISA was used
to quantify virus.
To evaluate the production of infectious virions,
supernatants from HIV-infected hepatocytes or Jurkats
were collected at day 3 post-infection and titered
using TZM-bl cells – a HeLa-derived indicator cell line
which expresses the β-galactosidase and luciferase
genes under the control of the HIV promoter [25].
1 × 105 TZM-bl cells were infected with supernatants
for two days, washed, and fixed with 1% (v/v) formalde-
hyde and 0.2% (v/v) glutaraldehyde in PBS. Following
several washes with PBS, TZM-bl cells were tested for
β-galactosidase activity with a solution of 4 mM
potassium ferrocyanide/ferricyanide, 2 mM MgCl2, and
0.4 mg/mL 5-bromo-4-chloro-3-indolyl-D-galactopyra-
noside (X-gal). The number of positive cells per well
was then counted.Quantification of integrated HIV DNA
After 4 hours of HIV infection, 5 × 105 cells were
washed and incubated for an additional 24 hours. For
experiments with antiviral drugs, cells were incubated
with 1–1000 uM of the integrase inhibitor raltegravir or
100uM of the reverse transcriptase inhibitor AZT before
and during HIV infection. 7,500 cells were then sus-
pended in lysis buffer containing 10 mM Tris HCl pH9,
0.1% Tween 20-NP40 and 400 μg/mL Proteinase K
(Invitrogen). Cellular lysates containing ~7,500 cells
were used to quantify integrated HIV DNA by nested
real time PCR as described elsewhere with minor modi-
fications [26,27]. Briefly, the first round amplification
used Alu sequence specific primers and the HIV-1 long
terminal repeat (LTR). This reaction was followed by a
second round of amplification with specific primers and
a specific labeled probe against the LTR performed in a
Light Cycler (Roche). Using the ACH-2 cell line, a line
of human T-lymphocytic leukemia that contains a single
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3 copies of integrated HIV DNA per reaction.Results
Detection of integrated HIV DNA in hepatocytes
To assess HIV infection of hepatocytes, we first exam-
ined whether the Huh7.5 and Huh7.5JFH1 cell lines could
support early steps in the HIV life cycle. As shown in
Figure 1A-B, both hepatocyte cell lines contained inte-
grated HIV DNA after infection with the CXCR4-
utilizing lab-adapted strain HIVNL4-3 that had been
DNase-treated to remove residual input DNA. Addition
of the integrase inhibitor raltegravir resulted in a dose-
dependent decrease in integrated HIV DNA levels in
both cell lines. Infection with the CCR5-utilizing lab-
adapted strain HIVYK-JRCSF resulted in similar levels of
integrated HIV DNA compared to HIVNL4-3 and was
also inhibited by raltegravir in a dose-dependent manner
(Figure 1C). The Jurkat lymphocyte cell line was evalu-
ated as a positive control, and demonstrated that HIV
integration was approximately 10-fold higher in lympho-
cytes compared to hepatocytes (Figure 1D). In this assay,
integrated HIV DNA was regularly tested for in 1)
DNase-treated stock virus preparations, 2) washes after
removal of residual unbound virus, and 3) mock infected
cell lines. In all cases, no integrated HIV DNA wasFigure 1 Detection of integrated HIV DNA in hepatocytes. Huh7.5 (A),
1, 10, 100, or 1000 uM of the integrase inhibitor raltegravir for one hour pr
were incubated in the presence of raltegravir for one hour prior to and du
HIV DNA was quantified in cell lysates by nested real-time PCR. Error bars rdetected, strongly suggesting that these findings were
not due to residual input virus.
Expression of p24 and production of infectious HIV in
hepatocytes
We next examined whether hepatocytes could also sup-
port late stages within the HIV life cycle. Because of the
high autofluorescence associated with hepatocytes, flow
cytometry was not an optimal choice for these experi-
ments; rather, cumulative HIV p24 antigen expression
was quantified in cell culture supernatants collected
from Huh7.5 cells infected with HIVNL4-3 at day 1
(47.0 ± 4.9 pg/mL), day 3 (115.1 ± 26.8 pg/mL), day 5
(165.7 ± 3.7 pg/mL), and day 7 (203.9 ± 9.8 pg/mL)
(Figure 2A). Incubation of Huh7.5 cells before and dur-
ing infection with 100 uM AZT resulted in a significant
decrease in p24 expression (61.4 ± 0.6 pg/mL).
These p24 levels in the supernatants of HIV-infected
Huh7.5 cells were lower than those observed after
HIVNL4-3 infection of the Jurkat lymphocyte cell line
(data not shown). Additionally, p24 protein expression
was detected at days 3, 5, and 7 post-infection via West-
ern Blot in HIV-infected Huh7.5JFH1 cell lysates, al-
though this approach was less sensitive than detection
via ELISA (Figure 2B).
To determine if HIV released from hepatocytes could
productively infect cells of non-hepatic origin, the TZM-Huh7.5JFH1(B), or Jurkat (D) cells were incubated in the presence of 0,
ior to and during infection with DNase-treated HIVNL4-3. Huh7.5 (C) cells
ring infection with DNase-treated HIVYK-JRCSF. After 24 hours, integrated
epresent the standard deviation between duplicates.
Figure 2 HIV protein expression in hepatocytes. (A) HIV p24 protein levels were quantified by ELISA in culture supernatants from Huh7.5 cells
infected with HIVNL4-3 at days 1, 3, 5, and 7 post-infection. Infection was also performed in the presence of 100 uM AZT for one hour prior to and
during infection. Error bars represent the standard deviation between duplicates. (B) Huh7.5JFH1 cells were incubated with HIVNL4-3. At days 1, 3, 5,
and 7 post-infection, cells were harvested, lysed, and subjected to Western Blot analysis using a rabbit monoclonal Ab (Epitomics) as the primary
Ab and a rabbit polyclonal Ab to mouse IgG from (Abcam) as the secondary Ab. As a loading control, GAPDH was detected using a rabbit
polyclonal Ab (Santa Cruz Biotechnology).
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collected on day 3 from HIV-infected hepatocytes. Cell
counts were 35.5 ± 9.2 or 49.0 ± 4.2 positive cells per well
after incubation with supernatants from Huh7.5 or
Huh7.5JFH1 cells infected with HIVNL4-3, while back-
ground values were 0.0 ± 0.0 positive cells for both cell
lines treated with the 5th wash of the HIV input or mock
infected cells (Figure 3A). Similarly, no positive cells
were detected in both cell lines after incubation with
100 ng AT-2-treated HIVNL4-3 or 100 uM AZT, suggest-
ing that there was no non-specific activation of the HIV
LTR and that TZM-bl positive cells were the result of
bona fide virion production. Incubation of Huh7.5 orFigure 3 Infectious HIV production in hepatocytes. TZM-bl indicator ce
infection from Huh7.5 or Huh7.5JHF1 cells (A) or Jurkat cells (B) infected wit
activity. The mean number of positive TZM-bl cells per well is shown with
β-gal expression was also evaluated in the presence of 100 uM AZT for onHuh7.5JFH1 cells with HIVYK-JRCSF-infected supernatants
gave similar results, although overall positivity was lower
(data not shown). When TZM-bl cells were incubated
with supernatants from HIVNL4-3-infected Jurkat cells,
the number of positive cells was 5125 ± 2651 per well
(Figure 3B) suggesting that production of virions is sig-
nificantly higher in Jurkats than hepatocyte cell lines.
HIV infection of primary hepatocytes
Because liver biopsies are not routinely performed in
HIV mono-infected persons in the absence of viral hepa-
titis, there are limited data on HIV infection of hepato-
cytes in vivo. Moreover, mechanical dissociation oflls were incubated with culture supernatants collected at day 3 post-
h HIVNL4-3 or 100 ng AT-treated HIVNL4-3and tested for β-galactosidase
the error bars representing the standard deviation between duplicates.
e hour prior to and during infection.
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ging due to the infrequency of liver transplantation in
HIV-positive indivixduals and the frequent cirrhosis that
is found in these patients. Therefore, we further exam-
ined whether HIV could infect primary hepatocytes
in vitro. Similar to the Huh7.5 and Huh7.5JFH1 cell lines,
integrated HIV DNA was detected in primary hepato-
cytes after infection with HIVNL4-3 (Figure 4A). In-
cubation of supernatants from HIV-infected primary
hepatocytes with the TZM-bl indicator cell line also
showed modest numbers of positive cells (21 ± 14.5;
Figure 4B). No TZM-bl positive cells were observed
using supernatants from primary hepatocytes that were
mock infected or exposed to AT-2-treated HIVNL4-3.
Conclusions
Several lines of evidence suggest the potential for HIV to
interact directly with multiple liver cell populations
in vivo (reviewed in [9]). For instance, HIV RNA and
proviral DNA have been detected in liver biopsies from
persons with HIV infection [28-30]. Subsequent immu-
nohistochemistry and in situ hybridization studies using
liver specimens from HIV-infected patients have demon-
strated HIV p24 protein and HIV RNA in Kupffer cells,
inflammatory mononuclear cells, sinusoidal cells, intra-
hepatic lymphocytes, and/or hepatocytes [28,31-35]. Effi-
cient activation of the HIV long terminal repeat alsoFigure 4 HIV infection of primary hepatocytes. (A) Primary
human hepatocytes were incubated with DNase-treated HIVNL4-3 for
two hours. After 24 hours, integrated HIV DNA was quantified in cell
lysates by nested real-time PCR. (B)TZM-bl indicator cells were
incubated with culture supernatants collected at day 3 post-
infection from primary human hepatocytes infected with HIVNL4-3 or
100 ng AT-2 treated HIVNL4-3 and tested for β-galactosidase activity.
The mean number of positive TZM-bl cells per well is shown with
the error bars representing the standard deviation between
duplicates. β-gal expression was also evaluated in the presence of
100 uM AZT for one hour prior to and during infection.occurs in hepatocytes [36-38]. HIV compartmentalization
in the liver has also been reported recently, suggesting
that viral adaptation for replication within the liver
may occur in vivo [30]. Soluble HIV proteins, such as
gp120, also induce caspase expression and hepatic apop-
tosis [39-41], as well as interleukin 8 (IL-8), a pro-
inflammatory chemokine that is an important mediator
of hepatic inflammation and is known to antagonize the
antiviral effects of IFN [42-45].
Despite multiple studies assessing the effects of HIV
proteins on hepatocytes in vitro, contradictory reports of
HIV entry receptor expression [39,40,46,47] may have
lessened enthusiasm for investigating the ability of HIV
to infect and replicate within hepatocytes. Nonetheless,
several recent reports provide evidence that HIV can
productively infect hepatocytes at low levels. For ex-
ample, Xiao et al. isolated a CD4-independent strain of
HIV from a patient with advanced HIV disease that was
capable of infecting hepatocyte cell lines, as well as pri-
mary hepatocytes [48]. Fromentin et al. demonstrated
that Huh7.5 cells bind to and internalize HIV particles
and that HIV infection of CD4+ T cells was enhanced
after interacting with virus-loaded hepatocytes compared
to cell-free virus [49]. Finally, Iser et al. observed
increased HIV reverse transcriptase activity following
HIV infection of hepatocyte cell lines [50]. While the
precise receptors used by HIV to enter hepatocytes re-
main elusive, Iser et al. reported that, despite the inabil-
ity to detect surface expression of CD4, CCR5, or
CXCR4 by flow cytometry, infection with R5 or X4 HIV
was inhibited by maraviroc or AMD3100, respectively,
suggesting CCR5- or CXCR4-dependent entry [50]. We
have also detected CCR1, CCR2, and CCR3 co-receptors
on Huh7.5 cells (Cardona-Maya and Blackard, unpub-
lished data). Therefore, these receptors may also contrib-
ute to HIV infection of hepatocytes, although this
requires additional investigation.
The current investigation was considered a proof-of-
principle study designed to assess whether HIV was cap-
able of infecting hepatocytes or not. Thus, several cell
lines (HCV infected and HCV uninfected), as well as
primary hepatocytes, were utilized. This study comple-
ments previous investigations and provides several novel
findings. First, the Huh7.5 and Huh7.5JFH1 cell lines, as
well as primary hepatocytes, supported early steps in the
HIV life cycle as demonstrated by detection of inte-
grated HIV DNA. Second, hepatocyte cell lines and pri-
mary hepatocytes also support late steps in the HIV life
cycle as demonstrated by p24 detection in the superna-
tants and/or lysates of infected cells and infection of an
HIV indicator cell line with hepatocyte-derived HIV.
This finding is particularly interesting in light of the re-
cent study by Fromentin et al. demonstrating that circu-
lating CD4+ T cells can be potentially infected with HIV
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suggest that replication of HIV in hepatocytes is occur-
ring at relatively low levels as integrated DNA levels in
hepatocytes were lower than levels in Jurkats. Similarly,
supernatants from HIV-infected hepatocytes contained
fewer HIV particles that were able to infect an indicator
cell line than HIV-infected Jurkats. These findings are
in agreement with other recent reports that hepatocytes
permit low-level replication of HIV [49,50].The levels of
HIV infection achieved in primary hepatocytes versus
hepatocyte cell lines were not equivalent. This may re-
flect differing levels of permissiveness to HIV in pri-
mary hepatocytes versus hepatocyte cell lines, possibly
due to different levels of entry receptors or innate anti-
viral defense molecules. Interestingly, single-cell cloning
has been utilized to examine permissiveness of Huh7
cells to HCV infection [51]. The finding of sub-
populations of the parental cell line with distinct
phenotypic characteristics implies that HIV infectivity
could also be impacted, although a comprehensive ana-
lysis of HIV infection of primary hepatocytes derived
from distinct patients has not been performed to date.
Thus, future studies that address the expression of HIV
entry receptors, as well as cellular factors that restrict
HIV infection should be examined in primary hepato-
cytes from multiple donors and correlated with overall
levels of HIV replication.
We were quite interested to find that HIV could in-
deed infect an HCV-infected hepatocyte cell line. In a
preliminary investigation, we found that HIV infection
of Huh7.5JFH1 cells resulted in increased positive- and
negative-sense HCV RNA levels, as well as increased
HCV protein expression, compared to HIV uninfected
cells [52]. However, HIV-induced HCV replication was
abolished in the presence of antiretroviral agents.
These data complement in vivo reports that HCV RNA
levels are elevated in individuals with HIV/HCV
co-infection compared to those with HCV mono-
infection [11,53,54] and suggest that the HCV-infected
Huh7.5JFH1 cell line could be developed as an in vitro
model to characterize mechanisms by which HIV and
HCV interact at the cellular level and contribute to
accelerated liver disease.
In conclusion, the present results demonstrate that the
Huh7.5 and Huh7.5JFH1 cell lines, as well as primary
hepatocytes, can be infected with HIV. These studies
provide the necessary systems to further expand our
understanding of virus-virus and virus-host interactions
that are relevant for enhancing our understanding of
how HIV impacts liver disease, as well as increased rep-
lication of hepatitis viruses. Moreover, these investiga-
tions could ultimately lead to optimization of current
therapies for HIV and ameliorate the deleterious effects
of HIV on liver disease.Competing interests
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